Your chemistry; our biology; more success

Gene Logic's partnership-based philosophy has guided its emergence as a leading provider of products and services across all three major segments of the drug development chain - drug discovery, pre-clinical and clinical. The clients have driven the evolution, and meeting their needs continually brings it closer to fulfilling the aspiration to be the most valued biology partner to the pharmaceutical industry.

The range of discovery subscription products and services - such as BioExpress(r) and ToxExpress(r) Systems - are used by the majority of leading names in the pharmaceutical industry. The BioExpress(r) System, built on over 18,000 extensively annotated human clinical samples, enables clients to analyse genes and gene expression profiles as an integral part of their drug development programs. The ToxExpress(r) System, with over 12,000 samples analysed from well-characterised reference compounds and proprietary predication algorithms helps industry leaders screen and identify lead compounds most likely to succeed in development and uncover the molecular cascade leading to adverse events and potential safety biomarkers.

The 2002 acquisition of TherImmune Research Corporation provides Gene Logic with resources and expertise in drug discovery and pre-clinical activities. Gene Logic operates full pre-clinical good laboratory practice (GLP) labs, with small and large animal facilities. Our laboratories provide services across species and routes of administration, backed by proven expertise in analytical services and regulatory compliance. More than 1,200 studies have been completed on behalf of clients, including general toxicology, reproductive and developmental toxicology, safety pharmacology and carcinogenicity.

To complement and leverage these capabilities, Gene Logic has added an important new capability - the Drug Repositioning and Selection(tm) Program. The acquisition of the drug repurposing platform of Millennium Pharmaceuticals gives Gene Logic leading technologies in rescuing and repositioning failed or struggling compounds. These efforts are aimed at returning these compounds to successful clinical development. Given the rising costs and lengthening time to bring a drug to market, clients must make the best possible use of every research and development investment. By thinking as a partner - listening to clients and understanding their needs - Gene Logic has taken important steps, designed to provide clients with the insights and expertise needed to find the full therapeutic and commercial potential within each drug in the developmental pipeline.

Gene Logic also provides a broad suite of clinical solutions. The team of clinicians, biostatisticians, regulatory experts and scientists offers complete pharmacogenomic solutions to improve this critical phase of drug development. They offer expertise in patient stratification, biomarker identification and in vivo mechanism of activity, clinical and regulatory consulting, as well as a proprietary method for processing and analysing whole blood.

Gene Logic's approach to doing business - a partnership approach, based upon finding the developmental solutions critical to the success of each drug, and each client - has driven growth and expansion of resources, technologies and areas of expertise. Today, Gene Logic's portfolio of products and services reflects a commitment to more than monetary investment. It is practical proof of the aspiration to be the most valued partner to the pharmaceutical industry

Further information
Gene Logic Inc.
Tel: +1 800 4363 5642
Fax : +1 301 987 1701
Email : info@genelogic.com
Website: www.genelogic.com